Physician profile
Paul E Otteson
NPI 1982030987
$1,026.40
in general payments reported to CMS, 2019-2025
18 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.85 · 2022: $82.40 · 2023: $109 · 2024: $295 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.16 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $228.71 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $168.52 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $149.92 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $95.40 | 2021-2025 | Taltz, Ebglyss |
| Amgen INC. | $56.78 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $49.93 | 2025 | |
| Incyte Corporation | $43.36 | 2023-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $39.56 | 2022-2025 | |
| Galderma Laboratories, L.P. | $35.66 | 2025 | Nemluvio |
| Ucb, INC. | $27.71 | 2023-2024 | Cimzia, Bimzelx |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $20.12 | 2024 | |
| Verrica Pharmaceuticals INC. | $19.17 | 2023 | Ycanth |
| Dermavant Sciences, INC. | $18.35 | 2024 | Vtama |
| Lnhc, INC | $16.22 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $15.06 | 2024 | Adbry |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $14.88 | 2025 | Zoryve |
| Organon LLC | $13.72 | 2025 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Otteson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.